| | Demographics | Total cohort n = 56 | Warfarin n = 39 | DOAC n = 17 | value |
| | Age, years, median, IQR | 72 (54,81) | 71 (52,81) | 74 (63,83) | 0.433 | | Male sex | 26 (46) | 16 (41) | 10 (59) | 0.219 | | Wt, kg (ABW), median, IQR | 72 (58,88) | 61 (50,71) | 65 (52,74) | 0.423 | | BMI, kg/m [2], median, IQR | 25 (22,31) | 25 (22,30) | 26 (21,33) | 0.397 | | EGFR, ml/min/1.73m2, median, IQR | 17 (8,24) | 14 (7,23) | 21 (12,28) | 0.021 | | Length of stay, days, median, IQR | 11 (7,21) | 14 (8,23) | 8 (4,11) | 0.006 |
| | Past medical history | | DVT | 8 (14) | 6 (15) | 2 (12) | 1.000 | | PE | 14 (25) | 10 (26) | 4 (24) | 1.000 | | Stroke | 9 (16) | 7 (18) | 2 (12) | 0.707 | | Ischemic | 7 (13) | 5 (12.8) | 2 (12) | 1.000 | | Hemorrhagic | 2 (5) | 2 (5) | 0 (0) | 1.000 | | Renal disease | | Stage 4 | 26 (46) | 14 (36) | 12 (71) | 0.017 | | Stage 5 | 30 (54) | 25 (64) | 5 (30) | 0.017 | | Hemodialysis | 25 (45) | 21 (54) | 4 (24) | 0.036 | | CAD | 19 (34) | 13 (33) | 6 (35) | 0.887 | | PAD/PVD | 7 (18) | 7 (18) | 0 (0) | 0.088 | | Liver disease | 1 (3) | 1 (3) | 0 (0) | 1.000 | | Active cancer | 4 (7) | 1 (3) | 3 (18) | 0.079 | | HF | 18 (32) | 12 (31) | 6 (35) | 0.739 | | Reduced EF | 8 (14) | 5 (42) | 3 (50) | 0.688 | | Preserved EF | 10 (18) | 7 (58) | 3 (50) | 1.000 | | DM | 23 (41) | 16 (41) | 7 (41) | 0.992 | | HTN | 46 (82) | 29 (74) | 17 (100) | 0.023 | | Prior bleeding | 4 (7) | 2 (5) | 2 (12) | 0.577 | | AF | 11 (20) | 7 (18) | 4 (24) | 0.719 | | CHA2DS2-VASc, median, IQR | 5 (4,7), n = 11 | 5 (4,6), n = 7 | 5 (3,7), n = 4 | 0.527 | | Anemia | 20 (36) | 16 (41) | 4 (24) | 0.209 | | Coagulopathy | 2 (5) | 2 (5) | 0 (0) | 1.000 | | Protein C/S deficiency | | 1 | 0 | | | Lupus anticoagulant | | 1 | 0 | | | Antithrombin deficiency | | 0 | 0 | | | Antiphospholipid antibody | | 0 | 0 | | | Factor V Leiden | | 0 | 0 | | | Major surgery or trauma in the past 6 months | 8 (14) | 5 (13) | 3 (18) | 0.688 |
| | Indication for anticoagulation | | DVT | 44 (79) | 30 (77) | 14 (82) | 0.738 | | PE | 14 (25) | 10 (26) | 4 (24) | 1.000 | | AF | 11 (20) | 7 (18) | 4 (24) | 0.719 | | Mechanical valve | 1 (3) | 1 (3) | 0 (0) | 1.00 |
| | Concomitant medications | | | | | | Aspirin | 25 (45) | 17 (44) | 8 (47) | 0.810 | | Clopidogrel | 3 (5) | 2 (5) | 1 (6) | 1.000 | | Ticagrelor | 1 (6) | 0 (0) | 1 (6) | 0.304 | | Darbepoetin alfa | 15 (27) | 13 (33) | 2 (12) | 0.114 |
|
|
All data presented as n (%) unless otherwise stated, BMI: body mass index, EGFR: estimated glomerular filtration rate, AF: atrial fibrillation, DVT: deep vein thrombosis, PE: pulmonary embolism, CAD: coronary artery disease, PAD: peripheral artery disease, PVD: peripheral vascular disease, DM: diabetes mellitus, HTN: hypertension, CHA2DS2-VASc: congestive heart failure, hypertension, age, diabetes mellitus, stroke/TIA/TE, vascular disease (prior MI, PAD, or aortic plaque), and sex category.
|
